Engaging stakeholders along health technology assessment pathways: a scoping review of international practice

30 September 2025 - Health technology assessment has been characterised as a complex adaptive system that centrally features stakeholder interactions.  ...

Read more →

Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride) in the UK at a list price equal to the US launch price

22 September 2025 - Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026.  ...

Read more →

PHARMAC proposes changes to make it easier to access HIV medicines

1 October 2025 - New Zealanders living with, or at risk of, HIV could soon benefit from proposed changes to ...

Read more →

New Zealand Pharmaceutical Schedule - 1 October 2025

1 October 2025 - The October 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...

Read more →

Schedule of Pharmaceutical Benefits - 1 October 2025

1 October 2025 - The October 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...

Read more →

AbbVie announces UK pricing strategy for Elahere (mirvetuximab soravtansine-gynx)

29 September 2025 - The list price will be consistent with the US to reflect the value of the innovation. ...

Read more →

New life changing medicines listed on the PBS

28 September 2025 - From 1 October 2025, Australians affected by breast cancer and rare kidney disease will have access ...

Read more →

Major breast cancer treatment cost slashed under new PBS listing

28 September 2025 - Thousands of women will pay significantly less for treatment after the Federal Government listed a leading ...

Read more →

Health Minister Mark Butler says PBS not for negotiation, Donald Trump announced 100 pc tariff on pharmaceutical goods

26 September 2025 - Health Minister Mark Butler says Australia’s PBS will be protected at all costs, despite a pending ...

Read more →

PHARMAC proposes funding five medicines and more convenient treatment options to ease pressure on health services

24 September 2025 - New Zealanders living with multiple sclerosis, breast cancer, eye conditions, and lung cancer could benefit from ...

Read more →

New subcutaneous formulation of Opdivo receives positive INESSS recommendation for multiple tumour types

23 September 2025 - Milestone decision recognises the value of SC formulation of Opdivo to help support delivery flexibility ...

Read more →

Push for taxpayers to fund weight loss drugs for 500,000 Australians

23 September 2025 - Danish pharmaceutical giant Novo Nordisk has asked the Federal Government to subsidise its blockbuster weight loss ...

Read more →

Cost barrier emerges for breakthrough Alzheimer’s drug in Australia

19 September 2025 - The first new Alzheimer’s drug approved for use in Australia in 25 years, ticked off by ...

Read more →

Biocon Biologics' Yesafili (aflibercept) now publicly funded in Ontario, Canada for the advanced treatment of patients with retinal diseases

18 September 2025 -  -- Biocon Biologics is pleased to announce that Yesafili (aflibercept), a biosimilar to Eylea (aflibercept) injection, ...

Read more →

PHARMAC proposes funding a new brand of ADHD medicine

17 September 2025 - PHARMAC is seeking feedback on a proposal to fund a new brand of methylphenidate to help ...

Read more →